0QCO Stock Overview
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QCO from our risk checks.
Pharming Group N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.75 |
| 52 Week High | €0.97 |
| 52 Week Low | €0.65 |
| Beta | 0.60 |
| 1 Month Change | -7.33% |
| 3 Month Change | -13.32% |
| 1 Year Change | -16.98% |
| 3 Year Change | -5.90% |
| 5 Year Change | -40.91% |
| Change since IPO | -92.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QCO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 5.5% | -1.0% | 1.6% |
| 1Y | -17.0% | -17.2% | 2.0% |
Return vs Industry: 0QCO matched the UK Biotechs industry which returned -17% over the past year.
Return vs Market: 0QCO underperformed the UK Market which returned 1% over the past year.
Price Volatility
| 0QCO volatility | |
|---|---|
| 0QCO Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0QCO has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0QCO's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 404 | Fabrice Chouraqui | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
| 0QCO fundamental statistics | |
|---|---|
| Market cap | €511.58m |
| Earnings (TTM) | -€10.46m |
| Revenue (TTM) | €262.43m |
1.9x
P/S Ratio-48.9x
P/E RatioIs 0QCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QCO income statement (TTM) | |
|---|---|
| Revenue | US$297.20m |
| Cost of Revenue | US$35.40m |
| Gross Profit | US$261.80m |
| Other Expenses | US$273.64m |
| Earnings | -US$11.84m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 88.09% |
| Net Profit Margin | -3.98% |
| Debt/Equity Ratio | 37.3% |
How did 0QCO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/23 11:11 |
| End of Day Share Price | 2025/04/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |
| Joseph Pantginis | H.C. Wainwright & Co. |